Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells

Journal of Immunology

Volumn 160, Issue 9, 1998, Pages 4449-4456

  Toes, René E M ^a   Van Der Voort, Ellen I H ^a   Schoenberger, Stephen P ^a   Drijfhout, Jan Wouter ^a   Van Bloois, Louis ^b   Storm, Gert ^b   Kast, W Martin ^c   Offringa, Rienk ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LIPID; LIPOSOME; SYNTHETIC PEPTIDE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EMBRYO; IMMUNIZATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; NORTHERN BLOTTING; ONCOGENE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR; TUMOR GROWTH; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DRUG CARRIERS; IMMUNE TOLERANCE; LIPOSOMES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR ESCAPE; VACCINATION;

EID: 0032080385     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kast, W. M., L. Roux, J. Curren, H. J. J. Blom, A. C. Voordouw, R. H. Meloen, D. Kolakofski, and C. J. M. Melief. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with an unbound peptide. Proc. Nat. Acad. Sci. USA 88:2283.
2. Schulz, M., R. M. Zinkernagel, and H. Hengartner. 1991. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 88:991.
3. Feltkamp, M. C. W., H. L. Smits, M. P. M. Vierboom, R. P. Minnaar, B. M. De Jongh, J. W. Drijfhout, J. Ter Schegget, C. J. M. Melief, and W. M. Kast. 1993. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242.
4. Minev, B. R., B. J. McFarland, P. J. Spiess, S. A. Rosenberg, and N. P. Restifo. 1994. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:4155.
5. McNeil, C. 1997. HPV vaccine treatment trials proliferate, diversify. J. Natl. Cancer Inst. 89:280.
6. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jäger, F. Brasseur, J. Herman, P. G. Coulie, and T. Boon. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883.
7. Huang, L., G. Soldevilla, M. Leeker, R. Flavell, and I. N. Crispe. 1994. The liver eliminates T cells undergoing antigen-triggered apoptosis. Immunity 1:741.
8. Singer, G. C., and A. K. Abbas. 1994. The fas antigen is involved in peripheral but not in thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:366.
9. Kearney, E. R., K. A. Pape, D. Y. Loh, and M. K. Jenkins. 1994. Visualization of peptide-induced T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327.
10. Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner, and H. Pitcher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182:261.
11. Toes, R. E. M., R. J. J. Blom, R. Offringa, W. M. Kast, and C. J. M. Melief. 1996. Functional deletion of tumor-specific cytotoxic T lymphocytes induced by peptide immunization can lead to the inability to reject tumors. J. Immunol 156: 3911.
12. Toes, R. E. M., R. Offringa, R. J. J. Blom, C. J. M. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855.
13. Kast, W. M., R. Offringa, P. J. Peters, A. C. Voordouw, R. H. Meloen, A. J. Van der Eb, and C. J. M. Melief. 1989. Eradication of adenovirus E1-induced tumors by E1a-specific cytotoxic T lymphocytes. Cell 59:603.
14. Toes, R. E. M., R. Offringa, H. J. J. Blom, R. M. P. Brandt, A. J. Van der Eb, C. J. M. Melief, and W. M. Kast. 1995. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J. Immunol 154:3396.
15. Ruley, H. E. 1983. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304:602.
16. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
17. Scheicher, C. M. Mehlig, R. Zecher, and K. Reske. 1992. Dendritic cells from mouse bone marrow: in vitro differentiation using low doses of recombinant granulocyte-macrophage colony-stimulating factor. J. Immunol. Methods 154: 253.
18. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. M. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
19. Steinman, R. M., G. Kaplan, M. D. Witmer, and Z. Cohn. 1979. Identification of a novel cell-type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J. Exp. Med. 149:1.
20. Gausepohl, H., M. Kraft, C. Boulin, and R. W. Frank. 1990. Automated multiple peptide synthesis with BOP activation. In 11th American Peptide Symposium. J. E. Rivier and G. R. Marshall, eds. ESCOM Science Publishers, Leiden, 1003.
21. Miyazawa, M., R. Fujisawa, C. Ishihara, Y. A. Takei, T. Shimizu, H. Uenishi, H. Yamagishi, and K. Kuribayashi. 1995. Immunization with a single T helper cell epitope abrogates Friend virus-induced erythroid proliferation and prevents late leukemia development. J. Immunol. 155:748.
22. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, A. Sette, and H. M. Grey. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
23. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:341.
24. Traversari, C., P. Van der Bruggen, B. Van den Eynde, P. Hainaut, C. Lemoine, N. Ohta, L. Old, and T. Boon. 1992. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous CTL. Immunogenetics 35:145.
25. Dal Monte, P., and F. C. Szoka. 1989. Effect of liposome encapsulation of antigen presentation in vitro: comparison of presentation by peritoneal macrophages and B cells. J. Immunol. 142:1437.
26. Harding, C. V., D. S. Collins, J. W. Slot, H. J. Geuze, and E. R. Unanue. 1991. Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells. Cell 64:393.
27. Lopes, L. M., and B. M. Chain. 1992. Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen. Eur. J. Immunol. 22:287.
28. Zhou, F., B. T. Rouse, and L. Huang. 1992. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J. Immunol. 149:1599.
29. Schild, H., M. Norda, K. Deres, K. Falk, O. Rötschke, K.-H. Wiesmüller, G. Jung, and H,-G. Rammensee. 1991. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. Exp. Med. 174:1665.
30. Allsop, C. E. M., M. Plebanski, S. Gilbert, R. E. Sinden, S. Harris, G. Frankel, G. Dougan, C. Hioe, D. Nixon, E. Paoletti, G. Layton, and A. V. S. Hill. 1996. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol 26:1951.
31. BenMohamed, L., H. Gras-Masse, A. Tartar, P. Daubersies, K. Brahimi, M. Bossus, A. Thomas, and P. Druilhe. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B. T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242.
32. Mayordomo, J. I., D. J. Loftus, H. Sakamoto, C. M. De Cesare, P. M. Appasamy, M. T. Lotze, W. J. Storkus, E. Appella, and A. B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357.
33. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective immunity. J. Exp. Med. 183:283.
34. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence of T cells. B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
35. Finkelman, F. D., A. Lees, R. Birnbaum, W. C. Gause, and S. Z. Morris. 1996. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157:1406.
36. Grohmann, U., R. Bianchi, E. Ayroldi, M. L. Belladonna, D. Surace, M. C. Fioretti, and P. Puccetti. 1997. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158:3593.
37. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
38. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol 5:849.
39. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
40. Zinkernagel, R. M., D. Moskophidis, T. Kündig, S. Oehen, H. Pircher, and H. Hengartner. 1993. Effector T-cell induction and T-cell memory versus peripheral deletion of T cells. Immunol. Rev. 131:199.
41. Schild, H., K. Deres, K.-H. Wiesmuller, G. Jung, and H.-G. Rammensee. 1991. Efficiency of peptides and lipopeptides for in vivo priming virus-specific cytotoxic T cells. Eur. J. Immunol. 21:2649.
42. + CTL in vivo with peptide vaccine constructs. J. Immunol 152:549.
43. Mayordomo, J. L. D. J. Loftus, H. Sakamoto, C. M. De Cesar, P. M. Appasamy, M. V. Lotze, W. J. Storkus, E. Appella, and A. B. de Leo. 1996. Therapy of murine tumors with dendritic cells pulsed with p53 wild type and mutant sequence peptides. J. Exp. Med. 183:1357.
44. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.